neuroClues and the EIC Accelerator: Eye Tracking for Parkinson's
P3Lab, founded in 2020 in Louvain-la-Neuve, Belgium, by Antoine Pouppez, Pierre Daye and Pierre Pouget and trading as neuroClues, makes a portable eye tracker for neurologists. Its EIC project describes "a first-of-a-kind portable, fast and easy to use eye tracking medical device" to help diagnose movement disorders "faster (from months to days)", and targets profitability by 2027 and "€70M ARR" by 2030, according to CORDIS.
The European Innovation Council granted €2,500,000 towards a €5.56 million project running from February 2023 to January 2027, and committed up to €9 million in equity. The first-period report says neuroClues V1.0 passed its safety tests, obtained an MDR certificate for CE marking "as a class IIA medical device", produced its first 10 devices and was "integrated in the biggest Parkinson's cohort in France". In April 2026 the company closed a €10 million Series A, TNW reported, bringing total funding including grants to more than €22 million.
Company file
- Legal entity
- P3Lab SRL, BE0750746841, Louvain-la-Neuve; office in Bordeaux
- Founded
- 16 July 2020
- Founders
- Antoine Pouppez, Pierre Daye, Pierre Pouget
- Product
- neuroClues eye tracker, CE-marked class IIa
- Investors
- White Fund, EIC Accelerator (equity), Invest.BW, Wallonie Entreprendre, business angels
- Staff
- 10.2 full-time equivalents (2025)
- EIC project
- 1 Feb 2023 to 31 Jan 2027, ongoing
Where neuroClues Stands Now
The Series A is to fund a commercial team, a push for US FDA clearance in 2026 and expansion in Europe. The device is part of the Iceberg cohort study at the Paris Brain Institute at La Salpêtrière Hospital, which is looking for early Parkinson's biomarkers, and the company has presented preliminary evidence of a marker detectable five years before imaging-confirmed diagnosis, TNW reported. Its April 2024 €5 million round was led by White Fund and the EIC.
The record
An eye tracker for neurologists, from CE mark to Series A
P3Lab, trading as neuroClues, won EIC blended finance to validate and launch its eye-tracking device. It gained a CE mark in January 2025 and raised a €10 million Series A in 2026. The EIC project runs until January 2027.
- Jul 2020P3Lab foundedLouvain-la-Neuve
- 2021Seed roundFirst outside funding€4.7M
- Oct 2022EIC Accelerator cut-offNeuroCluesblended finance
- Feb 2023EIC project starts€5.56M project€2.50M grant
- Apr 2024Pre-Series AWhite Fund and the EIC lead€5M
- Jan 2025CE markClass IIa medical device under MDR
- Apr 2026Series ACommercial team, FDA push€10M
- Jan 2027EIC project due to endClinical studies in EU and US
CORDIS, neuroClues and TNW.
"The V1.0 product is continuously being build and sold on the market."
P3Lab, first-period report to the EICThe Technology: 800 Images Per Eye Per Second
The headset records up to 800 infrared images per eye per second while a patient follows a moving target, and AI extracts eye movement biomarkers within minutes, replacing the neurologist's "follow my finger" test with measurements. TNW reports that one in four Parkinson's patients is misdiagnosed and that confirmation takes 13 months on average. The report says integrating the device into hospital IT systems became "one of the most complex tasks".
The money
Funding rounds and the EIC grant
TNW puts total funding since 2020 at more than €22 million including grants.
neuroClues, April 2024; TNW, April 2026. Values in € millions.
What the EIC Project Promised, and What CORDIS Shows
The EIC project
The EU grant covers 45% of a €5.6M project
The NeuroClues project runs from February 2023 to January 2027. The EIC also committed up to €9 million in equity.
CORDIS project 190152225. Values in € millions.
The project aims to show the device's usability with early-adopter neurologists, measure its clinical value in existing and company-sponsored studies in Europe and the US, and build a go-to-market plan. The first period delivered CE marking, a production process and a reimbursement analysis. The sponsored studies and US work are still to be reported, and the project runs until January 2027.
- CE markingDeliveredClass IIa, MDR.
- Industrial productionDeliveredFirst 10 devices built.
- Sponsored clinical studiesOngoingProject ends 2027.
- FDA clearancePendingTargeted for 2026.
The Money
P3Lab lost €1.98 million in both 2024 and 2025, and its gross margin turned negative, according to Companyweb. By the end of 2025 equity had fallen to €978,554 against debts of €5.40 million, months before the Series A closed. Belgian small-company accounts do not show revenue, so device sales are not public.
The accounts
Equity and result, 2022 to 2025
Equity fell to €978,554 at the end of 2025, before the Series A, while debts rose to €5.40 million. Average staff was 10.2 in 2025.
Companyweb, P3Lab BE0750746841, from National Bank of Belgium filings. Values in € millions.
What Cannot Be Checked
Questions for the EIC
How much of the up to €9 million in EIC equity has been invested, how many devices have been sold, what the clinical studies show and whether the 2027 profitability target still stands are not public.
Why Europe Should Care
TNW cites forecasts that the number of people with Parkinson's will double to 13 million by 2040. An objective test that fits into a standard consultation, as the company designed it to, could shorten diagnosis. The EIC is backing a European device with grant and equity; whether doctors adopt it is the test still ahead.
What the project promised
A clinically validated, market-ready eye tracker, profitability by 2027 and €70 million ARR by 2030.
What the record shows
A CE-marked device, a €10 million Series A, falling equity before the raise and no public sales figures.
The Verdict
CE-marked, not yet proven
neuroClues has obtained its CE mark and raised a Series A. With the EIC project still running, its clinical and commercial promises cannot yet be judged.
neuroClues and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
Industry
HealthMedical devices
- Focus
- Neurology devices
- Technologies
- Eye tracking
- Artificial intelligence
- Keywords
- Parkinson's disease
- Movement disorders
- Neurology
- Early diagnosis